Study Reveals Economic Case For Precision Medicine In Cancer Care

Queen’s University Belfast has conducted a study in collaboration with a team of precision healthcare economists and researchers from Salutem Insights, Diaceutics PLC and King’s College London. Precision oncology aims to develop medical treatments that target the molecular characteristics of an individual's tumour.

“Precision medicines can deliver affordable care for cancer patients. A precision oncology Companion Diagnostic (CDx) guidance can deliver health benefits at affordable cost,” Mark Lawler, Professor, Digital Health, Queen’s University Belfast, co-lead of Health Data Research UK’s Big Data for Complex Disease Research Driver Programme and senior author on the paper, explained.

Raymond Henderson, Senior Health Technology Assessment Manager, Salutem Insights and lead author on the paper said, “This study emphasises how a precise health economic approach can provide the evidence base to underpin the delivery of precision oncology for patients.”

“For the first time, we can assume, the actual lifecycle advantage of recovering patients lost to the diagnostic pathway with an investment in better testing,” Peter Keeling, CEO, Diaceutics and co-author of the study, averred.